Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis

Szymon Smereka; Wiktor Jabłoński; Julia Raszewska; Natalia Wolińska; Caterina Riccardi

doi:10.5114/dr.2025.158595

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

5/2025
vol. 112

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł przeglądowy

Efficacy, Safety, and Impact on the Quality of Life of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis

Szymon Smereka

¹

,

Wiktor Jabłoński

²

,

Julia Raszewska

³

,

Natalia Wolińska

⁴

,

Caterina Riccardi

⁵

Junior Physician, Municipal Specialist Hospital named after G. Narutowicza, Krakow, Poland
Junior Physician, Stefan Żeromski Specialist Hospital, SP ZOZ, Krakow, Poland
6th-Year Medical Student, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Junior Physician, Beskid Oncology Center - Municipal Hospital named after John Paul II, Bielsko-Biala, Poland
Junior Physician, University Hospital, Krakow, Poland

Dermatol Rev/Przegl Dermatol 2025, 112, 301-305

DOI: https://doi.org/10.5114/dr.2025.158595

Data publikacji online: 2025/12/30

Plik artykułu:

- Efficacy.pdf [0.17 MB]

Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Smereka S, Jabłoński W, Raszewska J, Wolińska N, Riccardi C. Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):301-305. doi:10.5114/dr.2025.158595.

APA

Smereka, S., Jabłoński, W., Raszewska, J., Wolińska, N.,  & Riccardi, C. (2025). Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis. Dermatology Review/Przegląd Dermatologiczny, 112(5), 301-305. https://doi.org/10.5114/dr.2025.158595

Chicago

Smereka, Szymon, Wiktor Jabłoński, Julia Raszewska, Natalia Wolińska,  and Caterina Riccardi. 2025. "Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis". Dermatology Review/Przegląd Dermatologiczny 112 (5): 301-305. doi:10.5114/dr.2025.158595.

Harvard

Smereka, S., Jabłoński, W., Raszewska, J., Wolińska, N.,  and Riccardi, C. (2025). Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis. Dermatology Review/Przegląd Dermatologiczny, 112(5), pp.301-305. https://doi.org/10.5114/dr.2025.158595

MLA

Smereka, Szymon et al. "Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 5, 2025, pp. 301-305. doi:10.5114/dr.2025.158595.

Vancouver

Smereka S, Jabłoński W, Raszewska J, Wolińska N, Riccardi C. Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):301-305. doi:10.5114/dr.2025.158595.

Metryki PlumX:

1. Machado Á., Torres T.: Guselkumab for the treatment of psoriasis. BioDrugs 2018, 32, 119-128.

2. Al-Salama Z.T., Scott L.J.: Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol 2018, 19, 907-918.

3. Tokuyama M., Mabuchi T.: New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 2020, 21, 7488.

4. Mease P.J., Rahman P., Gottlieb A.B., Kollmeier A.P., Hsia E.C., Xu X.L., et al.; DISCOVER-2 Study Group: Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020, 395, 1126-1136. Erratum in: Lancet 2020, 395, 1114

5. Deodhar A., Helliwell P.S., Boehncke W.H., Kollmeier A.P., Hsia E.C., Subramanian R.A., et al.; DISCOVER-1 Study Group: Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020, 395, 1115-1125. Erratum in: Lancet 2020, 395, 1114.

6. Megna M., Balato A., Raimondo A., Balato N.: Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther 2018, 18, 459-468.

7. Nakamura M., Lee K., Jeon C., Sekhon S., Afifi L., Yan D., et al.: Guselkumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb) 2017, 7, 281-292.

8. Hampton P., Borg E., Hansen J.B., Augustin M.: Efficacy of brodalumab and guselkumab in patients with moderate-to-severe plaque psoriasis who are inadequate responders to ustekinumab: a matching adjusted indirect comparison. Psoriasis 2021, 11, 123-131.

9. Thilakarathne P., Schubert A., Peterson S., Noel W., Patel B., Hassan F.: Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials. Rheumatol Ther 2024, 11, 457-474.

10. Sbidian E., Chaimani A., Garcia-Doval I., Doney L., Dressler C., Hua C., et al.: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2022, 5, CD011535. Update in: Cochrane Database Syst Rev 2023, 7, CD011535.

11. Blauvelt A., Papp K., Gottlieb A., Jarell A., Reich K., Maari C., et al.; IXORA-R Study Group: A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 2020, 182, 1348-1358.

Copyright: © 2025 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Indeks osobowy

Efficacy, Safety, and Impact on the Quality of Life of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis

Szymon Smereka 1 , Wiktor Jabłoński 2 , Julia Raszewska 3 , Natalia Wolińska 4 , Caterina Riccardi 5

Szymon Smereka

¹

,

Wiktor Jabłoński

²

,

Julia Raszewska

³

,

Natalia Wolińska

⁴

,

Caterina Riccardi

⁵